<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>National Heart and Lung Institute</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/317F1E6E-B604-499D-9FA5-7F0883CED9E9"><gtr:id>317F1E6E-B604-499D-9FA5-7F0883CED9E9</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:otherNames>J</gtr:otherNames><gtr:surname>Openshaw</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F0CF3F48-B22B-4A63-B51A-388F334BDF0D"><gtr:id>F0CF3F48-B22B-4A63-B51A-388F334BDF0D</gtr:id><gtr:firstName>Christopher</gtr:firstName><gtr:surname>Chiu</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FR502121%2F1"><gtr:id>ACD71DAD-0915-41AD-84DC-5B7CD225CF98</gtr:id><gtr:title>COPD-like airway inflammation during RSV infection of older volunteers: INFLAMMAGE</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/R502121/1</gtr:grantReference><gtr:abstractText>Based on extensive preclinical and clinical research, we hypothesise that RSV disease represents a dysregulated and over-exuberant inflammatory response to infection. Steroids have limited efficacy, and identification of druggable inflammatory pathways in severe RSV disease would be of great potential value. There are promising clinical assets ready for investigation, however, our ability to test novel therapeutics is limited by the currently available models of viral disease and clinical endpoints tied to disease processes. Observational studies of natural infection are constrained by sampling, timing and access. We therefore propose to extend the experimental human RSV infection studies established at Imperial College to investigate the pulmonary response to RSV infection in older adult non-smokers and smokers, with the development of novel clinical endpoints which can then be used to evaluate the possible impact of treatment with validated novel anti-inflammatory agents from GSK in human RSV disease and therefore in COPD.</gtr:abstractText><gtr:technicalSummary>Overall, the aims of this project are to investigate the mechanisms of inflammation in older adult volunteers during respiratory viral infection in vivo and in vitro to develop novel clinical end-points and biomarkers that correlate with infection outcome. In addition to elucidating the pathways involved in steroid-resistant inflammation triggered by viral infection, the future option of treatment with a validated novel therapeutic will allow us to determine if either reducing viral-driven inflammation or directly reducing viral load improves clinical outcome. The early Parts of this project will generate data which will enable selection of an appropriate clinical therapeutic agent for investigation.</gtr:technicalSummary><gtr:fund><gtr:end>2018-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2017-04-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>103959</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>2CF0E80A-307D-4EE2-95E4-F8D669ABF6B0</gtr:id><gtr:title>Group B streptococcus and respiratory syncytial virus immunisation during pregnancy: a landscape analysis.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1fc72bcbd5fd8bf785fad7b006ebc768"><gtr:id>1fc72bcbd5fd8bf785fad7b006ebc768</gtr:id><gtr:otherNames>Heath PT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>5a6b1beb870e77.93042863</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D50CBFEB-8B0E-44FD-B964-18A470B24799</gtr:id><gtr:title>Maternal immunisation: collaborating with mother nature.</gtr:title><gtr:parentPublicationTitle>The Lancet. Infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/23d2c8168942b16866f1d5c1e817c38e"><gtr:id>23d2c8168942b16866f1d5c1e817c38e</gtr:id><gtr:otherNames>Marchant A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1473-3099</gtr:issn><gtr:outcomeId>5a578cf96189c1.30074720</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D2CD581C-D700-40AB-934D-E7B914F9F28B</gtr:id><gtr:title>RSV Takes Control of Neonatal Breg Cells: Two Hands on the Wheel.</gtr:title><gtr:parentPublicationTitle>Immunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fba90e472cb39c17c5b6bac5bcdf10dc"><gtr:id>fba90e472cb39c17c5b6bac5bcdf10dc</gtr:id><gtr:otherNames>Openshaw PJM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1074-7613</gtr:issn><gtr:outcomeId>58c699d892faf1.13241153</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2426215F-CFE0-4BC3-B01E-A571803EA1D6</gtr:id><gtr:title>Nasosorption as a Minimally Invasive Sampling Procedure: Mucosal Viral Load and Inflammation in Primary RSV Bronchiolitis.</gtr:title><gtr:parentPublicationTitle>The Journal of infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c351901b4b975887bba786afddf71ad8"><gtr:id>c351901b4b975887bba786afddf71ad8</gtr:id><gtr:otherNames>Thwaites RS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-1899</gtr:issn><gtr:outcomeId>5a578d5cbe2711.40417741</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>91A9827E-6999-4403-957A-FA28E42FE517</gtr:id><gtr:title>Protective and Harmful Immunity to RSV Infection.</gtr:title><gtr:parentPublicationTitle>Annual review of immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fba90e472cb39c17c5b6bac5bcdf10dc"><gtr:id>fba90e472cb39c17c5b6bac5bcdf10dc</gtr:id><gtr:otherNames>Openshaw PJM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0732-0582</gtr:issn><gtr:outcomeId>58c699d90c5247.94803445</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8EBD69F0-6D7B-48F4-ADDA-67334B677D73</gtr:id><gtr:title>M1-like monocytes are a major immunological determinant of severity in previously healthy adults with life-threatening influenza.</gtr:title><gtr:parentPublicationTitle>JCI insight</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f02aa2ebb10d042b908ae932541a85e1"><gtr:id>f02aa2ebb10d042b908ae932541a85e1</gtr:id><gtr:otherNames>Cole SL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2379-3708</gtr:issn><gtr:outcomeId>5a578c31b42918.94303695</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>886A6E29-6BC0-4B06-A842-1634D1E7B2F5</gtr:id><gtr:title>Vaccines in the Prevention of Viral Pneumonia.</gtr:title><gtr:parentPublicationTitle>Clinics in chest medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8d04cfae86dbf76ca65a38e48c692dd0"><gtr:id>8d04cfae86dbf76ca65a38e48c692dd0</gtr:id><gtr:otherNames>Fraser CS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0272-5231</gtr:issn><gtr:outcomeId>58c699d820cf10.35258397</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/R502121/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>